ReviewFrontiers in pharmacology2025
Polyphenolic metabolites in
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to elucidate the therapeutic effects of polyphenolic metabolites from Materials and methods: This review was conducted based on a comprehensive literature search of the PubMed, NCBI, and Google Scholar databases from their inception until August 2025. Key search terms included "Scutellaria baicalensis", "Scutellaria baicalensis and polyphenols," "Ischemic stroke," "cerebral infarction," "cerebral ischemia-reperfusion injury," and "toxicity." The article first summarizes the polyphenolic metabolites of S. baicalensis, such as baicalein, baicalin, wogonin, wogonoside, scutellarin, chrysin, apigenin, chlorogenic acid, and ferulic acid, and provides an overview of the pathophysiological mechanisms of ischemic stroke. The primary focus lies on elucidating the pharmacological mechanisms, potential toxic effects, and strategies for improving the bioavailability of these polyphenols in the treatment of ischemic stroke. Results: The polyphenolic metabolites of Conclusion: The polyphenolic metabolites of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.